Last reviewed · How we verify

NCT03938870

CNS Tau Kinetics in Healthy Aging and Alzheimer's Disease

Completed Last updated 13 February 2024
What this trial tests

trial testing L-Leucine 13C6 in Alzheimer's Disease in 96 participants. Completed in 6 July 2023.

Timeline
18 August 2015
Primary endpoint
6 July 2023
6 July 2023

Quick facts

Lead sponsorWashington University School of Medicine
StatusCompleted
Study typeOBSERVATIONAL
Enrollment96
Start date18 August 2015
Primary completion6 July 2023
Estimated completion6 July 2023
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Washington University School of Medicine

Who can join

18 and older, any sex, with Alzheimer's Disease or Brain Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Alzheimer's disease (AD) is the most common cause of dementia and currently has no disease modifying treatments or simple accurate diagnostic tests. The goal of this project is to study how tau (a protein thought to cause AD) is made, transported and cleared in the human body. Better understanding of these processes may lead to improved understanding of AD, earlier diagnosis and a way to evaluate treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Alzheimer's Disease

Currently open trials in the same condition.

Other Washington University School of Medicine trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03938870.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing